Dusquetide

Summary

Dusquetide is an investigational synthetic peptide classified as an innate defense regulator. It is being studied for its ability to modulate the host innate immune response, reduce inflammation and enhance bacterial clearance, with clinical focus on chemotherapy‑induced oral mucositis and aphthous ulcers in Behçet's syndrome.

Mechanism of Action

Dusquetide binds to the ZZ domain of the autophagy‑receptor protein SQSTM1/p62, forming electrostatic and hydrophobic contacts that alter the p62‑RIP1 complex. This interaction increases p38 MAPK phosphorylation and up‑regulates CEBP/B transcription without triggering autophagy. The peptide penetrates cell membranes, acts on tissue‑resident cells, and subsequently activates myeloid‑derived cells, leading to enhanced bacterial clearance and modulation of pro‑ and anti‑inflammatory cytokines.

What the Research Shows

Preclinical mouse and hamster studies showed a ~50% reduction in the duration of chemotherapy‑induced oral mucositis, a finding reproduced in a phase 2a randomized, placebo‑controlled trial where severe oral mucositis was cut by half and infection rates fell. Structural work using NMR and crystallography identified the dusquetide‑p62 binding site and clarified downstream signaling. An open‑label pilot in eight Behçet's patients receiving intravenous dusquetide reported reductions in ulcer number, pain and duration, with no serious adverse events. Together, these data suggest immunomodulatory and anti‑infective activity, but are limited to early‑phase investigations.

Reported Benefits

Evidence from animal models and a phase 2a trial indicates dusquetide can halve the duration and severity of oral mucositis and lower associated infection risk. A small Behçet's pilot suggests possible relief of aphthous ulcer burden. The peptide’s mechanism of targeting host pathways may avoid traditional antibiotic resistance.

Limitations of the Evidence

The clinical data are confined to a single randomized phase 2a study and a very small open‑label pilot; sample sizes are modest and long‑term outcomes are unknown. No large, double‑blind trials have been reported, and efficacy outside the studied indications remains untested. Safety data are limited to short‑term observations.

Safety Considerations

Both the phase 2a mucositis study and the Behçet's pilot reported that dusquetide was well tolerated, with no treatment‑related adverse events or serious safety signals noted. However, comprehensive safety profiling, including rare or delayed effects, has not been established in larger populations.

How It Is Administered

Dusquetide has been administered intravenously in the Behçet's pilot and investigated via oral and subcutaneous routes in other studies. Formulations are peptide solutions suitable for injection or oral delivery; specific dosing regimens have not been disclosed in the cited literature.

Routes of Administration

Goals & Uses

• Acceleration of mucosal healingTissue RepairModerate
• Preservation of anti-tumor and antimicrobial immunityImmune ModulationLow
• Oral mucositis preventionOncology Supportive CareModerate
• Improvement in quality of life during cancer treatmentSupportive Oncology CareModerate
• Inflammatory bowel diseaseGastroenterologyLow
• Reduction of oral mucositis severityAnti Inflammatory / Mucosal ProtectionModerate

Contraindications

• Known hypersensitivity to Dusquetide or excipientsAllergyHigh
• Known hypersensitivity to dusquetide or any component of the formulationAllergy/hypersensitivityHigh

Adverse Effects

• Injection site reactionsLocalUncommon
• HeadacheNeurologicCommonPain in the head or upper neck
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• FatigueGeneralCommonLow energy or tiredness
• DiarrheaGastrointestinalUncommonLoose or frequent stools

Drug Interactions

• Concurrent immunosuppressantsModerate
• Cytotoxic chemotherapy agents (e.g., cisplatin, carboplatin)Low
• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk

Population Constraints

• Severe renal or hepatic impairmentOrgan FunctionRelative
• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveRelative
• Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionInvestigationalNo marketing authorization; clinical studies in progress.
• United StatesInvestigationalIND holder; Phase III trials ongoing.

Investigational New Drug (IND) status in the US; not approved in any jurisdiction.

Evidence & Sources

• A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy
  Journal ArticleModerateNorth JR, et al.2016-01-01T00:00:00.000000Z
• Protocol to identify drug-binding sites in proteins using solution NMR spectroscopy
  Journal ArticleLowPenumutchu S, et al.2022-01-01T00:00:00.000000Z
• Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study
  Journal ArticleModerateKudrimoti M, et al.2016-01-01T00:00:00.000000Z
• Linker-Free Synthesis of Antimicrobial Peptides Using a Novel Cleavage Reagent: Characterisation of the Molecular and Ionic Composition by nanoESI-HR MS
  Journal ArticleLowSegovia R, et al.2023-01-01T00:00:00.000000Z
• Dusquetide modulates innate immune response through binding to p62
  Journal ArticleLowZhang Y, et al.2022-01-01T00:00:00.000000Z
• Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome
  Journal ArticleModerateDonini O, et al.2026-01-01T00:00:00.000000Z

Frequently Asked Questions